New Soul music
''Science Signaling'' to Publish Paper on Therapeutically Targeting ErbB3 to Treat Overexpressed or Mutated Oncogenes Merrimack Pharmaceuticals Chief Scientific Officer Ulrik B. Nielsen is Senior Author
Staff Writer
2009-06-29
.www.streetroachpics.com .
This paper describes how the authors used a systems biology approach to highlight ErbB3 as a key node in cancer progression and to design a human monoclonal antibody with a novel mechanism that potently inhibits ErbB3 and may potentially benefit patients not effectively treated by current therapies targeting overexpressed or mutated oncogenes. MM-121 is currently being evaluated in clinical trials. (PRWeb Jun 26, 2009)
Read the full story at http://www.prweb.com/releases/2009/06/prweb2579654.htm
http://www.prweb.com/releases/2009/06/prweb2579654.htm
